## Abstract In this prospective study of 34 patients with Parkinson's disease (PD), measurements of the short duration levodopa motor response have been performed every 3 years in defined __off__ states. The mean time from initiation of levodopa treatment was 14.8 years, and 17 patients survived to
Longitudinal study of the motor response to levodopa in Parkinson's disease
β Scribed by Benjamin G. Clissold; Craig D. McColl; Katrina R. Reardon; Mark Shiff; Peter A. Kempster
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 132 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
In this prospective study of 34 patients with Parkinson's disease, measurements of the short duration levodopa motor response have been performed in defined off states at 3 yearly intervals over a mean period of 11.4 years from the point of commencement of levodopa treatment. Twentyβtwo patients were still available for study; 10 had died and 2 were lost to followβup. The levodopa motor response amplitude increases over the first 5 years of treatment, and thereafter, on and off scores worsen in parallel with conservation of the response. Patients who developed motor fluctuations within the first 5 years of treatment had, on average, a stronger response to levodopa with significantly better on phase motor function (P = 0.003). Although the proportion of βmidlineβ motor disability (affecting gait, balance, and cranial motor function) increases with time, these deficits do not actually become unresponsive to levodopa. Patients who developed dementia had a significantly more rapid decline in motor function. The latest graph of serial scores for the whole cohort shows an upward curving or exponential increase in motor disability after the first decade of treatment. Applying a notional untreated disability line to this graphβan estimate of the disability that would have accrued if drugs had never been givenβwe suggest that the longβduration response to levodopa eventually runs down with disease progression. Β© 2006 Movement Disorder Society
π SIMILAR VOLUMES
OBJECTIVE: To monitor comparative progression of clinical impairment over 4 years in patients with Parkinson's disease (PD) who present on levodopa at two different levels of Hoehn and Yahr (HY) stages, II and III. BACKGROUND: The rate of clinical impairment progression in patients with PD being tr
## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KWβ6002) is an adenosine A~2A~ receptor a